Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT Dose Escalation for LAPC
NCT02873598Phase 1Completed
- Sponsor
- University of Colorado Denver
- Start
- Nov 2016
- Primary completion
- Jun 2019
- Countries
- 1
01
Overview
Phase 1, open-label trial in pancreatic cancer (PC) (3 arms), sponsored by University of Colorado Denver. Primary endpoint: Maximum Tolerated Dose of Stereotactic Body Radiotherapy at 3 months. Started Nov 2016; status: completed.
02
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT02873598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02873598.